Furthermore, the findings revealed that a cumulative defined daily dose of DPP-4 inhibitors of more than 392 and an intake duration of more than 1.49 years were also significantly associated with a decreased risk of HCC. The gene discussed is DPP4; the disease is hepatocellular carcinoma.